Numinus Wellness Inc. is a Canadian health-care company focused on the research, development and delivery of psychedelic-assisted therapies. The firm operates through integrated business units encompassing clinic operations, research and development, and laboratory services. Numinus works to advance mental health treatment options by leveraging compounds such as psilocybin, MDMA, ketamine and other psychedelic molecules under evidence-based protocols.
Through its clinic division, Numinus offers guided psychedelic-assisted psychotherapy, ketamine infusion services and support programs at licensed treatment centres in select Canadian provinces. These centres employ trained therapists, medical professionals and support staff to administer treatment in controlled environments. The company also provides digital tools and training resources designed to standardize care pathways and track patient outcomes over time.
Numinus Bioscience, the company’s laboratory arm, operates a Health Canada-licensed facility in Vancouver, British Columbia. This laboratory performs quality testing, extraction and formulation support for psychedelic compounds, as well as bridging research partnerships with academic institutions. Numinus Bioscience’s capabilities include chromatographic analysis, microbiology screening and custom formulation services to ensure product consistency and safety for clinical research and therapeutic use.
Founded in 2019 (formerly Organto Wellness), Numinus is led by founder and CEO Payton Nyquvest, who has guided the company through a strategic pivot toward psychedelic medicine. Headquartered in Vancouver, Numinus continues to build its network of treatment centres and research collaborations, with a vision of expanding access to innovative mental health solutions across North America.
AI Generated. May Contain Errors.
Free LKYSF Stock Alerts